Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.275 AUD | +1.85% | +10.00% | +14.58% |
Mar. 15 | Nova Eye Medical Completes Retail Entitlement Offer | MT |
Feb. 22 | Nova Eye Medical Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Sales 2024 * | 22M 14.42M | Sales 2025 * | 30.7M 20.12M | Capitalization | 61.78M 40.48M |
---|---|---|---|---|---|
Net income 2024 * | -8M -5.24M | Net income 2025 * | -1M -655K | EV / Sales 2024 * | 2.49 x |
Net cash position 2024 * | 7M 4.59M | Net cash position 2025 * | 4.4M 2.88M | EV / Sales 2025 * | 1.87 x |
P/E ratio 2024 * |
-6.18
x | P/E ratio 2025 * |
-21.8
x | Employees | 301 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.39% |
Latest transcript on Nova Eye Medical Limited
1 day | +1.85% | ||
1 week | +10.00% | ||
Current month | +19.57% | ||
1 month | +19.57% | ||
3 months | -1.79% | ||
6 months | +34.15% | ||
Current year | +14.58% |
Managers | Title | Age | Since |
---|---|---|---|
Thomas Spurling
CEO | Chief Executive Officer | - | 11-03-30 |
David Lubeck
CTO | Chief Tech/Sci/R&D Officer | - | 18-10-17 |
Mark Flynn
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Victor Previn
FOU | Founder | 65 | 84-12-31 |
Thomas Spurling
CEO | Chief Executive Officer | - | 11-03-30 |
Rahmon Coupe
BRD | Director/Board Member | 60 | 13-05-14 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 0.275 | +1.85% | 150 249 |
24-04-24 | 0.27 | +1.89% | 536,808 |
24-04-23 | 0.265 | +3.92% | 300,127 |
24-04-22 | 0.255 | +2.00% | 132,153 |
24-04-19 | 0.25 | -5.66% | 129,987 |
Delayed Quote Australian S.E., April 26, 2024 at 01:35 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+14.58% | 40.18M | |
+7.71% | 218B | |
+6.25% | 182B | |
+10.60% | 132B | |
+26.73% | 108B | |
-0.65% | 62.51B | |
+15.42% | 52.98B | |
-1.89% | 47.59B | |
-1.91% | 39.96B | |
+11.16% | 39.22B |
- Stock Market
- Equities
- EYE Stock